Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cyclacel Pharmaceuticals, Inc. CYCCP
$14.31
-$1.65 (-11.56%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
27210021.00000000
-
week52high
22.58
-
week52low
6.05
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.11038000
-
EPS
-2.04700000
-
Last Dividend
0.60000000
-
Next Earnings Date
12 мая 2020 г. в 20:00
Описание компании
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | 30 апр 2021 г. | |
| Roth Capital | Buy | 05 сент 2018 г. | |
| H.C. Wainwright | Buy | 16 окт 2015 г. | |
| JMP Securities | Market Perform | Market Outperform | 17 дек 2014 г. |
| JMP Securities | Market Outperform | 02 июл 2013 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kirschbaum Mark | A | 31200 | 31200 | 31 янв 2023 г. |
| Rombotis Spiro George | A | 62588 | 57600 | 31 янв 2023 г. |
| McBarron Paul | A | 31492 | 31200 | 31 янв 2023 г. |
| Ferguson Kenneth M. | A | 47467 | 47467 | 14 июн 2022 г. |
| Ferguson Kenneth M. | A | 23733 | 23733 | 14 июн 2022 г. |
| Ferguson Kenneth M. | A | 27733 | 27733 | 14 июн 2022 г. |
| BARKER SAM L | A | 31645 | 31645 | 14 июн 2022 г. |
| BARKER SAM L | A | 19196 | 15822 | 14 июн 2022 г. |
| HENNEY CHRISTOPHER S | A | 31645 | 31645 | 14 июн 2022 г. |
| HENNEY CHRISTOPHER S | A | 18196 | 15822 | 14 июн 2022 г. |
Новостная лента
Cyclacel Pharmaceuticals Inc. (CYCC) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 19:59
Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Grace Kim - IR Spiro Rombotis - CEO Mark Kirschbaum - CMO Paul McBarron - CFO Conference Call Participants Ahu Demir - Ladenburg Thalmann Shubhendu Sen Roy - Brookline Capital Markets Operator Good afternoon, and welcome to the Cyclacel Pharmaceuticals First Quarter 2023 Results Conference Call and Webcast. At this time, all participants are in a listen-only mode.
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
GlobeNewsWire
04 мая 2023 г. в 09:15
BERKELEY HEIGHTS, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2023 financial results on Thursday, May 11, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
GlobeNewsWire
07 мар 2023 г. в 09:15
BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that the Company plans to participate in a fireside chat and host one-on-one meetings at two investor conferences.
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2022 Earnings Call Transcript
Seeking Alpha
06 мар 2023 г. в 21:04
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC ) Q4 2022 Earnings Conference Call March 6, 2023 4:30 PM ET Company Participants Irina Koffler - Investor Relations Spiro Rombotis - President and Chief Executive Officer Paul McBarron - Executive Vice President, Finance and Chief Operating Officer Mark Kirschbaum - Senior Vice President and Chief Medical Officer Conference Call Participants Jonathan Aschoff - ROTH MKM Ahu Demir - Ladenburg Jeff Jones - Oppenheimer Kemp Dolliver - Brookline Capital Markets Operator Good afternoon and welcome to the Cyclacel Pharmaceuticals Fourth Quarter and Full Year 2022 Results Conference Call and Webcast. [Operator Instructions] Please note, today's call is being recorded.
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
GlobeNewsWire
27 февр 2023 г. в 09:15
BERKELEY HEIGHTS, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2022 financial results on Monday, March 6, 2023. The Company will host a conference call at 4:30pm ET on the same day.